Rahmqvist I, Dahlstrand Rudin A, Mellstrom E, Ibrahim RR, Andersson D, Pujol Calderon F, Ordqvist Redfors A, Rostamzadeh N, Franssila W, Karlsson C, Zetterlund F, Khashan R, Frostdahl H, Osterlund T, Ek T, Fagman H, Stahlberg A, Dalin M. Patient-specific sequencing panels enable sensitive circulating tumor DNA analysis in rhabdomyosarcoma independent of genetic profile. [Journal and year to confirm]. doi:10.1038/s41698-025-01147-6

Micallef P, Luna Santamaria M, Escobar M, Andersson D, Osterlund T, Mouhanna P, Filges S, Johansson G, Fagman H, Vannas C, Stahlberg A. Digital sequencing is improved by using structured unique molecular identifiers. [Journal and year to confirm]. https://doi.org/10.1038/s41698-025-01147-6

Andersson D, Kristiansson H, Luna Santamaria M, Zafar H, Mijakovic I, Torinsson Naluai A, Stahlberg A. Evaluation of automatic cell free DNA extraction metrics using different blood collection tubes. [Journal and year to confirm]. doi:10.1038/s41598-025-03508-4

Mouhanna P, Stahlberg A, Andersson D, Albu-Kareem A, Elinder E, Eriksson O, Kavanagh A, Kovacs A, Larsson KF, Linderholm B, Uminska M, Osterlund T, Howell SJ, Ekholm M. Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirements. Int J Cancer. 2024. doi:10.1002/ijc.35292

Andersson D, Kebede FT, Escobar M, Osterlund T, Stahlberg A. Principles of digital sequencing using unique molecular identifiers. Mol Aspects Med. 2024. doi:10.1016/j.mam.2024.101253

Rahmqvist I, Engstrom E, Mellstrom E, Ibrahim R, Pujol Calderon F, Dahlstrand Rudin A, Ordqvist Redfors A, Rostamzadeh N, DiRienzo R, Franssila W, Khashan R, Xylander M, Karlsson C, Ek T, Andersson D, Osterlund T, Gaarder J, Fagman H, Fransson S, Martinsson T, Stahlberg A, Dalin M. Personalized circulating tumor DNA analysis for sensitive disease monitoring and detection of relapse in neuroblastoma. Biomark Res. 2024. doi:10.1186/s40364-024-00688-5

Elliott K, Kumar Singh V, Backerholm A, Ogren L, Lindberg M, Soczek KM, Hoberg E, Luijts T, van den Eynden J, Falkenberg M, Doudna J, Stahlberg A, Larsson E. Mechanistic basis of atypical TERT promoter mutations. Nat Commun. 2024. doi:10.1038/s41467-024-54158-5

Ek T, Ibrahim RR, Vogt H, Georgantzi K, Trager C, Gaarder J, Djos A, Rahmqvist I, Mellstrom E, Pujol-Calderon F, Vannas C, Hansson L, Fagman H, Treis D, Fransson S, Osterlund T, Chuang TP, Verhoeven BM, Stahlberg A, Palmer RH, Hallberg B, Martinsson T, Kogner P, Dalin M. Long-lasting response to lorlatinib in patients with ALK-driven relapsed or refractory neuroblastoma monitored with circulating tumour DNA analysis. Cancer Res Commun. 2024;4(9):2553-2564. doi:10.1158/2767-9764.CRC-24-0338

Rodin W, Szeponik L, Rangelova T, Tamiru Kebede F, Osterlund T, Sundstrom P, Hogg S, Wettergren Y, Cosma A, Stahlberg A, Bexe Lindskog E, Quiding Jarbrink M. gamma-delta T cells in human colon adenocarcinomas comprise mainly Vd1, Vd2, and Vd3 cells with distinct phenotype and function. Cancer Immunol Immunother. 2024. doi:10.1007/s00262-024-03758-7

Vannas C, Escobar M, Osterlund T, Andersson D, Mouhanna P, Soomagi A, Molin C, Wennergren D, Fagman H, Stahlberg A. Treatment monitoring of a patient with synchronous metastatic angiosarcoma and breast cancer using ctDNA. Int J Mol Sci. 2024. doi:10.3390/ijms25074023

Sidstedt M, Gynna AH, Kiesler KM, Jansson L, Steffen CR, Hakansson J, Johansson G, Osterlund T, Bogestal Y, Tillmar A, Radstrom P, Stahlberg A, Vallone PM, Hedman J. Ultrasensitive sequencing of STR markers utilizing unique molecular identifiers and the SiMSen-Seq. Forensic Sci Int Genet. 2024. doi:10.1016/j.fsigen.2024.103047

Luna Santamaria M, Andersson D, Parris TZ, Helou K, Osterlund T, Stahlberg A. Digital RNA sequencing using unique molecular identifiers enables ultrasensitive RNA mutation analysis. Commun Biol. 2024. doi:10.1038/s42003-024-05955-7

Schoultz E, Liang S, Carlsson T, Filges S, Stahlberg A, Fagman H, Wiel C, Sayin V, Nilsson M. Tissue specificity of oncogenic BRAF targeted to lung and thyroid through a shared lineage factor. iScience. 2023. doi:10.1016/j.isci.2023.107071

Crescitelli R, Filges S, Karimi N, Urzi O, Alonso-Agudo T, Stahlberg A, Lotvall J, Lasser C, Olofsson Bagge R. Extracellular vesicle DNA from human melanoma tissues contains cancer-specific mutations. Front Cell Dev Biol. 2022. doi:10.3389/fcell.2022.1028854

Zhou Q, et al. Persistence of ctDNA in patients with breast cancer during neoadjuvant treatment is a significant predictor of poor tumor response. Clin Cancer Res. 2022. doi:10.1158/1078-0432.CCR-21-3231

Osterlund T, Filges S, Johansson G, Stahlberg A. UMIErrorCorrect and UMIAnalyzer: software for consensus read generation, error correction, and visualization using unique molecular identifiers. Clin Chem. 2022. doi:10.1093/clinchem/hvac136

Filges S, Mouhanna P, Stahlberg A. Digital quantification of chemical oligonucleotide synthesis errors. Clin Chem. 2021. doi:10.1093/clinchem/hvab136

Johansson G, Berndsen M, Lindskog S, Osterlund T, Fagman H, Muth A, Stahlberg A. Monitoring circulating tumor DNA during surgical treatment in patients with gastrointestinal stromal tumors. Mol Cancer Ther. 2021. doi:10.1158/1535-7163.MCT-21-0403

Ny L, Jespersen H, Karlsson J, Alsen S, Filges S, All-Eriksson C, Andersson B, Carneiro A, Helgadottir H, Levin M, et al. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. Nat Commun. 2021. doi:10.1038/s41467-021-25332-w

Vannas C, Bjursten S, Filges S, Fagman H, Stahlberg A, Levin M. Dynamic ctDNA evaluation of a patient with BRAFV600E metastatic melanoma demonstrates the utility of ctDNA for disease monitoring and tumor clonality analysis. Acta Oncol. 2020. doi:10.1080/0284186X.2020.1802064

Johansson G, Kaltak M, Rimniceanu C, Singh AK, Lycke J, Malmestrom C, Huhn M, Vaarala O, Cardell S, Stahlberg A. Ultrasensitive DNA immune repertoire sequencing using unique molecular identifiers. [Journal and year to confirm]. doi:10.1093/clinchem/hvaa159

Bjursten S, Vannas C, Filges S, Puls F, Pandita A, Fagman H, Stahlberg A, Levin M. Response to BRAF/MEK inhibition in A598_T599insV BRAF mutated melanoma. Case Rep Oncol. 2020. doi:10.1159/000504291

He HJ, Stein EV, Konigshofer Y, Forbes T, Tomson FL, Garlick R, Yamada E, Godfrey T, Abe T, Tamura K, et al. Multilaboratory assessment of a new reference material for quality assurance of cell-free tumor DNA measurements. J Mol Diagn. 2019. doi:10.1016/j.jmoldx.2019.03.006

Egyud M, Tejani M, Pennathur A, Luketich J, Sridhar P, Yamada E, Stahlberg A, Filges S, Krzyzanowski P, Jackson J, et al. Detection of circulating tumor DNA in plasma: a potential biomarker for esophageal adenocarcinoma. Ann Thorac Surg. 2019. doi:10.1016/j.athoracsur.2019.04.004

Filges S, Yamada E, Stahlberg A, Godfrey T. Impact of polymerase fidelity on background error rates in next-generation sequencing with unique molecular identifiers/barcodes. Sci Rep. 2019. doi:10.1038/s41598-019-39762-6

Johansson G, Andersson D, Filges S, Li J, Muth A, Godfrey TE, Stahlberg A. Considerations and quality controls when analyzing cell-free tumor DNA. Biomol Detect Quantif. 2019. doi:10.1016/j.bdq.2018.12.003

Egyud M, Sridhar P, Devaiah A, Yamada E, Saunders S, Stahlberg A, Filges S, Krzyzanowski P, Kalatskaya I, Jiao W, et al. Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer. Head Neck. 2019. doi:10.1002/hed.25563

Elliott K, Bostrom M, Filges S, Lindberg M, Van den Eynden J, Stahlberg A, Clausen AR, Larsson E. Elevated pyrimidine dimer formation at distinct genomic bases underlies promoter mutation hotspots in UV-exposed cancers. PLoS Genet. 2018. doi:10.1371/journal.pgen.1007849

Fredriksson NJ, Elliott K, Filges S, Van den Eynden J, Stahlberg A, Larsson E. Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature. PLoS Genet. 2017. doi:10.1371/journal.pgen.1006773

Stahlberg A, Krzyzanowski PM, Egyud M, Filges S, Stein L, Godfrey T. Simple multiplexed PCR-based barcoding of DNA for ultrasensitive mutation detection by next-generation sequencing. Nat Protoc. 2017;12(4):664-682. doi:10.1038/nprot.2017.006

Stahlberg A, Krzyzanowski PM, Jackson JB, Egyud M, Stein L, Godfrey TE. Simple, multiplexed, PCR-based barcoding of DNA enables sensitive mutation detection in liquid biopsies using sequencing. Nucleic Acids Res. 2016. doi:10.1093/nar/gkw224